T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
676
Patrick Industries
PATK
$2.78B
| $81.2M | 0.01% |
748,904
+112,766
| +18% | +$11.8M |
|
677
UL Solutions
ULS
$15.5B
| $81M | 0.01% |
1,027,413
+150,679
| +17% | +$12.1M |
|
678
CoStar Group
CSGP
$13.3B
| $80.6M | 0.01% |
1,198,832
-65,330
| -5% | -$4.63M |
|
679
Cheniere Energy
LNG
$55.2B
| $80.6M | 0.01% |
414,680
+31,077
| +8% | +$6.53M |
|
680
Replimune Group
REPL
$1.43B
| $80.3M | 0.01% |
8,262,296
-44,137
| -0.5% | -$375K |
|
681
Monte Rosa Therapeutics
GLUE
$1.35B
| $80.3M | 0.01% |
5,118,904
+481,844
| +10% | +$6.49M |
|
682
NOV
NOV
$7.36B
| $79.1M | 0.01% |
5,059,400
+4,785,015
| +1,744% | +$71M |
|
683
Carnival Corporation Ltd
CCL
$39.1B
| $78.5M | 0.01% |
2,571,039
+191,786
| +8% | +$5.35M |
|
684
Insulet
PODD
$10.1B
| $78.4M | 0.01% |
275,880
+40,284
| +17% | +$12.6M |
|
|
GLXY
685
Galaxy Digital Inc
GLXY
$4.11B
| $77.8M | 0.01% |
3,481,577
-4,441,006
| -56% | -$138M |
|
686
Applied Optoelectronics
AAOI
$11.3B
| $77.7M | 0.01% |
2,229,757
+2,188,630
| +5,322% | +$65.3M |
|
687
Atlassian
TEAM
$41.9B
| $76.9M | 0.01% |
474,362
+338,951
| +250% | +$53.2M |
|
688
New York Times
NYT
$10.4B
| $76.5M | 0.01% |
1,101,538
+31,484
| +3% | +$1.95M |
|
689
First Bancorp
FBP
$4.49B
| $75.9M | 0.01% |
3,659,149
+171,580
| +5% | +$3.54M |
|
690
Beam Therapeutics
BEAM
$2.74B
| $75.7M | 0.01% |
2,730,282
+467,133
| +21% | +$11.9M |
|
691
Douglas Emmett
DEI
$1.99B
| $75.5M | 0.01% |
6,873,763
-164,820
| -2% | -$2.07M |
|
692
Ford
F
$55.3B
| $75.2M | 0.01% |
5,733,688
+26,224
| +0.5% | +$338K |
|
693
Enpro
NPO
$7.1B
| $75.1M | 0.01% |
350,948
+85,667
| +32% | +$18.9M |
|
694
Realty Income
O
$59.7B
| $75M | 0.01% |
1,330,679
-1,613,917
| -55% | -$93.4M |
|
695
Tyler Technologies
TYL
$13.5B
| $74.7M | 0.01% |
164,518
+2,407
| +1% | +$1.15M |
|
696
Life Time Group Holdings
LTH
$9.89B
| $73.9M | 0.01% |
2,779,259
+230,993
| +9% | +$6.01M |
|
697
Loar Holdings
LOAR
$6.95B
| $73.7M | 0.01% |
1,083,474
+8,184
| +0.8% | +$597K |
|
698
Jabil
JBL
$38.8B
| $73.4M | 0.01% |
321,759
-88,747
| -22% | -$18.9M |
|
699
Entergy
ETR
$49.8B
| $73.2M | 0.01% |
791,622
+1,741
| +0.2% | +$165K |
|
700
monday.com
MNDY
$3.95B
| $72.9M | 0.01% |
493,760
-987,735
| -67% | -$166M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.